Medizin: Novartis verkündet Studienerfolg von MS-Mittel
Medikamente gegen Multiple Sklerose brachten in der Vergangenheit oft starke Nebenwirkungen wie Leberschäden mit sich. Das neue Mittel von Novartis soll das ändern.
Frankfurt - Swiss pharmaceutical company Novartis has announced positive results from key studies on its MS medication Remibrutinib. The company plans to seek worldwide approval for the drug in the treatment of relapsing MS, according to a statement released on Tuesday. Novartis' shares subsequently rose nearly five percent in response to the news.
However, the positive momentum was tempered by setbacks in another area of research: after three deaths, the company had to suspend several studies involving an experimental cell therapy. Investor attention remained focused on the encouraging data for Remibrutinib. In the two phase-III studies, the drug significantly reduced the annual relapse rate of patients compared to the French competitor Sanofi's medication Aubagio.
Additionally, inflammatory brain lesions were reduced, and the progression of physical limitations was delayed. Novartis also emphasized the drug's favorable safety profile, noting that there were no signs of liver damage in the studies. Despite progress in treatment, the company acknowledged that there remains an unmet need for oral therapies that effectively prevent relapses. Detailed data are expected to be presented at an MS conference in Toronto, Canada, in October.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
